Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1369-1371

  Kanda, J ^a   Ichinohe, T ^a   Saito, T ^a   Yamashita, K ^a   Kondo, T ^a   Ishikawa, T ^a   Ichiyama, S ^a   Uchiyama, T ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b Kitano Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BUSULFAN; CIPROFLOXACIN; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOFLOXACIN; MELPHALAN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANIMUSTINE; TOSUFLOXACIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BLOODSTREAM INFECTION; CANCER MORTALITY; CANCER SURVIVAL; CROSS RESISTANCE; DRUG EFFICACY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; LETTER; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RISK FACTOR; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BACTERIAL INFECTIONS; BONE MARROW TRANSPLANTATION; FLUOROQUINOLONES; HUMANS; MIDDLE AGED; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREMEDICATION; RETROSPECTIVE STUDIES; SAFETY-BASED DRUG WITHDRAWALS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77955571096     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.344     Document Type: Letter

References (10)

1. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004; 33: 735-739.
2. Yeh SP, Hsueh EJ, Yu MS, Wu H, Wang YC. Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal. Bone Marrow Transplant 1999; 24: 1207-1211.
3. Menichetti F, Felicini R, Bucaneve G, Aversa F, Greco M, Pasquarella C et al. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant 1989; 4: 489-492.
4. Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005; 24: 832-838.
5. Frere P, Hermanne JP, Debouge MH, Fillet G, Beguin Y. Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2002; 29: 589-594.
6. Saito T, Yoshioka S, Iinuma Y, Takakura S, Fujihara N, Ichinohe T et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hemato- logy-oncology unit. Eur J Clin Microbiol Infect Dis 2008; 27: 209-216.
7. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59: 5-22.
8. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-118.
9. Martino R, Subira M, Altes A, Lopez R, Sureda A, Domingo- Albos A et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 1998; 99: 206-211.
10. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64: 159-204.